165 related articles for article (PubMed ID: 23187773)
21. Treatment strategies for myeloma bone disease.
Berenson JR
Oncology (Williston Park); 2003 Dec; 17(12):1678, 1681-2. PubMed ID: 14723007
[No Abstract] [Full Text] [Related]
22. Bisphosphonate anticancer activity in multiple myeloma.
Terpos E
Anticancer Agents Med Chem; 2012 Feb; 12(2):123-8. PubMed ID: 21864228
[TBL] [Abstract][Full Text] [Related]
23. New treatment strategies provide more options for patients with breast cancer.
Hampton T
JAMA; 2008 Jul; 300(4):381-2. PubMed ID: 18647973
[No Abstract] [Full Text] [Related]
24. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
[No Abstract] [Full Text] [Related]
25. Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.
Phillips JM; Thibodeaux JD; Nathan C
Laryngoscope; 2010; 120 Suppl 4():S175. PubMed ID: 21225773
[TBL] [Abstract][Full Text] [Related]
26. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural AU; Avcu F
Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
[No Abstract] [Full Text] [Related]
28. Medical management update: multiple myeloma.
Stoopler ET; Vogl DT; Stadtmauer EA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May; 103(5):599-609. PubMed ID: 17291793
[TBL] [Abstract][Full Text] [Related]
29. Managing multiple myeloma.
Lee AS; Tsang RY; Sandhu I
CMAJ; 2021 Aug; 193(34):E1349. PubMed ID: 34462295
[No Abstract] [Full Text] [Related]
30. Zoledronic acid in metastatic bone disease: an audit based discussion.
Akbar RA; Gosh SK; Khalil S; ul Haq SM
J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
[TBL] [Abstract][Full Text] [Related]
31. The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..
Gnant M; Eidtmann H
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S2-6. PubMed ID: 20427029
[No Abstract] [Full Text] [Related]
32. [Treatment for multiple myeloma: current status and future strategy in Japan].
Iida S
Rinsho Ketsueki; 2008 Oct; 49(10):1368-73. PubMed ID: 18833921
[No Abstract] [Full Text] [Related]
33. Treatment of multiple myeloma bone disease: experimental and clinical data.
Papamerkouriou YM; Kenanidis E; Gamie Z; Papavasiliou K; Kostakos T; Potoupnis M; Sarris I; Tsiridis E; Kyrkos J
Expert Opin Biol Ther; 2015 Feb; 15(2):213-30. PubMed ID: 25388648
[TBL] [Abstract][Full Text] [Related]
34. Criticality of kyphoplasty and vertebroplasty.
Verdoia C; Macchi V; Bernieri J; Corradini C
Aging Clin Exp Res; 2011 Apr; 23(2 Suppl):47-8. PubMed ID: 21970921
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates in multiple myeloma: a fractured consensus.
Kumar SK
Leuk Lymphoma; 2015 Mar; 56(3):553-4. PubMed ID: 25224456
[No Abstract] [Full Text] [Related]
36. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Joshi AD; Carter JA; Botteman MF; Kaura S
Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
[TBL] [Abstract][Full Text] [Related]
37. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
Diel I; Aebi S
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
[No Abstract] [Full Text] [Related]
38. Synergistic antimyeloma effects of zoledronate and simvastatin.
Schmidmaier R; Simsek M; Baumann P; Emmerich B; Meinhardt G
Anticancer Drugs; 2006 Jul; 17(6):621-9. PubMed ID: 16917207
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
Ararat E; Sahin I; Ozdemir E; Altundag K
Br J Haematol; 2010 Dec; 151(5):530-1. PubMed ID: 20880117
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
